In a phase 2a clinical trial (NCT03976401), treatment of Efruxifermin in NASH patients (F1-F3 stage) indicated that the absolute changes from baseline in hepatic fat fraction were decreased in a dose-dependent manner, namely 12.3% (28 mg), 13.4% (50 mg), and 14.1% (70 mg) compared to 0.3% in the placebo group
She took the time to thoroughly explain my condition and the treatment options available, ensuring I felt comfortable and informed every step of the way
Subjective hypnotic efficacy of trazodone and zolpidem in DSMIIIR primary insomnia
Trastuzumab deruxtecan versus treatment of physicians choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
2016, doi: 10.1111/andr.12191